The U.S. Food and Drug Administration has opened a pilot program designed to streamline the investigational new drug (IND) application process for phase 1 trials. The agency had teased the initiative over the summer and has now made it operational, according to a report from Fierce Biotech.
The program is intended to address sluggish early-stage clinical trial launches in the United States. By expediting the IND pathway, the FDA hopes to bring U.S. phase 1 trials closer to the pace seen in China, where trial initiation has generally been faster. The source does not provide details on specific eligibility criteria or timelines, so those remain unclear.
Overall, the pilot marks a regulatory effort to reduce friction in early drug development. The source notes only this single development, with no comparison to prior programs or independent commentary, so the full impact is yet to be measured.